title: Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population.
abstract: OBJECTIVE
  Fas ligand (FasL) is an apoptotic agent and a member of tumor necrosis factor (TNF) family. FasL exists in cytotoxic T lymphocyte (CTL) and natural killer (NK) cells, and it is increased in tumor cell membrane. On the contrary, CTL and NK are bound to Fas on the surfaces of cell membrane; this triggers apoptosis in cytotoxic cells and leads to their death. This system plays an important role in eliminating viral infections and cancer cells. Malfunction of this system results in the development and spread of the malignancy. This study aims at evaluating the influence of Fas and FasL gene polymorphism in papillary thyroid cancer (PTC) in the Turkish population.
  
  
  METHODS
  Forty-five patients with PTC and 100 healthy controls were included in this study. The diagnosis of PTC was confirmed by histopathologic examination after surgery. The evaluation of genotype for Fas 670 A/G and FasL 843 C/T gene polymorphism was performed using the PCR-restriction fragment length polymorphism (RFLP) method.
  
  
  RESULTS
  The evaluation of Fas/FasL genotype and gene allele frequency did not show statistically significant differences between the patient and control group (p>0.05). In addition, the univariate analysis did not reveal a statistically significant relationship between the size of the nodule and the Fas/FasL gene polymorphism in patients with PTC.
  
  
  CONCLUSIONS
  As in other types of malignancy, genetic factors in the pathogenesis of PTC may also show changes in different populations. Fas/FasL gene polymorphysms are possible that different mechanisms function in apoptosis balance in PTC development.
authors.affiliation: Department of Endocrinology and Metabolism Disease, Ege University Medical School, Bornova, Izmir, Turkey. drmerdogan61@yahoo.com
authors.forename: M
authors.initials: M
authors.lastname: Erdogan
authors.forename: M
authors.initials: M
authors.lastname: Karadeniz
authors.forename: A
authors.initials: A
authors.lastname: Berdeli
authors.forename: S
authors.initials: S
authors.lastname: Tamsel
authors.forename: Y
authors.initials: Y
authors.lastname: Ertan
authors.forename: H
authors.initials: H
authors.lastname: Uluer
authors.forename: C
authors.initials: C
authors.lastname: Yilmaz
authors.forename: M
authors.initials: M
authors.lastname: Tuzun
authors.forename: T
authors.initials: T
authors.lastname: Kabalak
authors.forename: A G
authors.initials: AG
authors.lastname: Ozgen
mesh_terms: D000328:Adult; D017209:Apoptosis / Q000235:genetics; D002291:Carcinoma, Papillary / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D053222:Fas Ligand Protein / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease / Q000453:epidemiology; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D013964:Thyroid Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D014421:Turkey / Q000453:epidemiology; D019014:fas Receptor / Q000235:genetics*
chemical_list: D053222:Fas Ligand Protein; D019014:fas Receptor